



Auro Laboratories Limited

314, T.V. Industrial Estate, S.K. Ahire Marg
Worli, Mumbai – 400 030. India
Tel .: + 91 22 6663 5456
Fax : + 91 22 6663 5460
Email : auro@aurolabs.com
Web : www.aurolabs.com
Reg. Off / Mfg. Unit :
K-56, M.I.D.C. Tarapur,
Dist. Palghar, Maharashtra – 401506
CIN No. L33125MH1989PLC051910

May 25, 2024

The Listing Department
BSE Limited
Phiroz Jeejeebhoy Towers
Dalal Street, Fort, Mumbai - 400 001

Scrip : 530233
ID/Code
Subject : **Outcome of Board Meeting dated May 25, 2024**
Ref : **Regulation 30 & Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

We wish to inform you that the Board of Directors of the Company at their Meeting held today (i.e. May 25, 2024) has inter-alia:

1. Considered and approved the Audited Financial Results of the Company for the quarter and year ended on March 31, 2024 as recommended by the Audit Committee. In this regard, we are enclosing herewith:
 - Audited Financial Results for the quarter and year ended on March 31, 2024 along with the statement of assets and liabilities of the Company and Cash flow statement as on that date
 - Auditor's Report on the Financial Results for the quarter and year ended on March 31, 2024
 - Declaration regarding Auditor Report with unmodified opinion on the Audited Standalone Financial Results of the Company for the Financial Year ended on March 31, 2024.

The results are also being uploaded on website of the Company at www.aurolabs.com. The results will be published in the newspapers in terms of Regulation 47(1)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 in due course.

2. Convening the 35th Annual General Meeting of members of the Company on Friday, June 28, 2024, through Video-Conferencing ("VC") and Other Audio-Visual Means ("OAVM") in accordance with relevant circulars issued by the Ministry of Corporate Affairs, Government of India and Securities and Exchange Board of India.


The meeting of the Board of Directors commenced at 04.00 PM and concluded at 09:45 PM.

Kindly take the above on your record.

Thanking you,

Yours Faithfully,

For, Auro Laboratories Limited



(Siddhartha Deorah)
Whole Time Director
DIN: 00230796



Encl: A/a

AURO LABORATORIES LIMITED

CIN NO. :- L33125MH1989PLC051910

Regd. Office : K - 56 M.I.D.C INDUSTRIAL AREA, TARAPUR

BOISAR, DIST. PALGHAR 401506 , MAHARASHTRA

Tel.: +91-22-66635456 Fax:+91-22-66635460 Email. auro@aurolabs.com Web: www.aurolabs.com


ANNEXURE - I

PART - I

(Rs. In Lakhs except EPS)

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2024


Sr. No.	Particulars	Quarter Ended			Year Ended	
		31.03.2024	31.12.2023	31.03.2023	31.03.2024	31.03.2023
		(Ref. Note 4)	(Unaudited)	(Ref. Note 4)	(Audited)	(Audited)
1	Revenue from Operations	1,206.29	1,797.84	1,352.49	5,363.52	5,289.42
2	Other Income	39.85	42.27	61.93	150.39	94.13
3	Total Income (1 + 2)	1,246.14	1,840.11	1,414.42	5,513.91	5,383.55
4	Expenses					
	a. Cost of raw material consumed	576.48	761.61	634.03	2,903.70	3,730.48
	b. Purchase of Stock-in-trade	-	-	0.00	-	-
	c. Changes in inventories of finished goods, work-in-progress and stock in trade	(136.51)	204.24	120.64	(247.98)	(161.01)
	d. Employee benefits expense	213.33	122.11	142.57	514.38	472.38
	e. Finance Cost	(32.49)	44.48	13.41	73.57	81.42
	f. Depreciation and amortisation expenses	28.24	27.00	30.42	109.24	107.42
	g. Other Expenses	312.01	301.88	220.14	1,126.43	808.30
	Total Expenses (4)	961.06	1,461.32	1,161.21	4,479.34	5,038.99
5	Profit / (Loss) before exceptional and extraordinary items and tax (3 ± 4)	285.08	378.79	253.21	1,034.57	344.56
6	Exceptional items					
7	Profit / (Loss) before tax (5 ± 6)	285.08	378.79	253.21	1,034.57	344.56
8	Tax expense					
	(a) Current tax expenses for current year	71.75	105.38	74.67	274.08	100.08
	(b) MAT credit (where applicable)					
	(c) Deferred tax	(18.73)	-	0.28	(18.73)	0.28
9	Profit / (Loss) for the period from continuing operation (7 ± 8)	232.05	273.41	178.26	779.21	244.20
10	Profit / (Loss) for discontinuing operations		-			
11	Tax expense of discontinuing operations		-			
12	Profit / (Loss) for discontinuing operation (after tax) (10 ± 11)		-			
13	Profit / (Loss) for the period (after tax) (9 ± 12)	232.05	273.41	178.26	779.21	244.20
14	Other Comprehensive Income					
	A. Items that will not be reclassified subsequently to profit or loss					
	(i) Items that will not be reclassified to profit or loss	42.94	26.14	48.85	42.94	48.85
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(10.81)	(7.27)	(13.59)	(10.81)	(13.59)
	B. Items that will be reclassified subsequently to profit or loss		-			
	(i) Items that will be reclassified to profit or loss		-			
	(ii) Income tax relating to items that will be reclassified to profit or loss		-			
	Total other comprehensive income /(loss), net of tax (14)	32.13	18.87	35.26	32.13	35.26
15	Total Comprehensive Income for the period [comprising Profit/(Loss) for the period (after tax) and other comprehensive income (after tax)] (13 ± 14)	264.19	292.28	213.52	811.35	279.46
16	Paid-up equity share capital (Face value of Rs. 10 each)	623.25	623.25	623.25	623.25	623.25
17	Other Equity					
18	Earnings per share (EPS) (Face Value - Rs. 10 per Equity Shares)					
	(a) Basic	3.72	4.39	2.86	12.50	3.92
	(b) Diluted	3.72	4.39	2.86	12.50	3.92



Notes on financial results:-

- 1) The above audited financial results for the quarter and year ended 31st March, 2024, were reviewed by the Audit Committee and thereafter approved by the Board of Directors at meeting held on 25th May, 2024.
- 2) The Company operates in single segment i.e. "Pharmaceuticals", and hence does not have any additional disclosures to be made under Ind As 108 on operating Segments.
- 3) The above audited results, published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, have been prepared in accordance with Indian Accounting Standards (IND AS) notified under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015; Companies (Indian Accounting Standards) (Amendment) Rules, 2016 and guidelines issued by the Securities and Exchange Board of India (SEBI) and other accounting principles generally accepted in India.
- 4) Figures of the Quarter ended on 31st March, 2024 & 31st March, 2023 are the balancing figures between audited figures in respect of the full financial year and the published year to the date upto the third quarter of the respective financial year.
- 5) Figures for the Previous period have been regrouped/reclassified wherever necessary to conform to current period's classifications.
- 6) Pursuant to the Master Circular No. SEBI/HO/DDHS/PoD1/P/CIR/2023/119 dated 10 August 2021 issued by the SEBI with respect to the SEBI (Issue and Listing of Non-Convertible Securities) Regulations, 2021, the Company is not a Large Corporate as per the applicability criteria given under the Chapter XII of the aforesaid circular.

**FOR & BEHALF OF BOARD OF DIRECTORS
AURO LABORATORIES LIMITED**



**(SIDDHARTHA DEORAH)
WHOLE TIME DIRECTOR
DIN: 00230796**



Place : Mumbai
Date : 25.05.2024

Auro Laboratories Limited


Statement of Assets and Liabilities (Ind AS)

(Rs. In Lakh)

Particulars	As at 31.03.2024	As at 31.03.2023
	Audited	Audited
A ASSETS		
1. Non-Current Assets		
(a) Property, Plant and Equipment	2215.03	1,261.56
(b) Capital Work -in-Progress	3268.07	766.76
(c) Investment Property		-
(d) Financial Assets		
(i) Investments	4.88	4.88
(ii) Loans	-	-
(iii) Others	-	-
(e) Other non-current assets	-	-
2. Current assets		
(a) Inventories	823.97	1,175.58
(b) Financial Assets	-	-
(i) Investments	-	-
(ii) Trade Reveivables	1339.23	1,240.47
(iii) Cash and cash equivalents	99.22	178.72
(iv) Bank balances other than (iii) above	65.67	62.97
(v) Loans	-	-
(vi) Others	710.73	908.47
(c) Other Current Assets		-
TOTAL ASSETS	8526.79	5599.41
B EQUITY AND LIABILITIES		
1. Equity		
(a) Equity Share Capital	623.25	623.25
(b) Other Equity	3572.57	2,796.80
2. Liabilities		
(I) Non-Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	1,837.81	175.84
(ii) Other Financial Liabilities	-	25.50
(b) Provisions		
(c) Deferred Tax Liabilities (Net)	146.23	164.93
(II) Current Liabilities		-
(a) Financial Liabilities		
(i) Borrowings	786.57	440.00
(ii) Trade Payables	1,203.35	1,148.03
(b) Other Current Liabilities	82.93	118.99
(c) Provisions	274.08	106.07
(d) Current Tax Liabilities (net)		-
TOTAL EQUITY AND LIABILITIES	8526.79	5599.41

0.00

FOR & BEHALF OF BOARD OF DIRECTORS
AURO LABORATORIES LIMITED



(SIDDHARTHA DEORAH)
WHOLE TIME DIRECTOR
DIN: 00230796



Place : Mumbai
Date : 25.05.2024

Auro Laboratories Limited

Cash Flow Statement


Particulars	For the year ended 31.03.2024		For the year ended 31.03.2023	
	Amount	Amount	Amount	Amount
A. Cash flow from operating activities				
Net Profit / (Loss) before extraordinary items and tax		1,034.57		344.57
Add: Adjustments for:				
Depreciation and amortisation	109.24		107.42	
Other Non Cash Items	32.13		34.88	
Finance costs	73.57	214.94	81.42	223.72
		1,249.51		568.29
Less: Adjustment for:				
Interest income	6.65		10.49	
Dividend income	0	6.65	0.02	10.51
Operating profit / (loss) before working capital changes		1,242.86		557.78
Changes in working capital:				
Adjustments for (increase) / decrease in operating assets:				
Inventories	351.61		(750.12)	
Trade receivables	(98.76)		120.87	
Short Loans and advances	197.74		(171.53)	
Other Bank Balance	-		(0.46)	
Other non-current assets		450.59		(801.24)
		1,693.45		(243.46)
Adjustments for increase / (decrease) in operating liabilities:				
Trade payables	55.32		661.81	
Other current liabilities	(36.06)		(44.81)	
Other long-term liabilities				
Short-term provisions	168.01		(45.41)	
Long-term provisions				
		187.27		571.59
		1,880.72		328.13
Cash flow from extraordinary items				
Cash generated from operations		1,880.72		328.13
Net income tax (paid) / refunds				
Net cash flow from / (used in) operating activities (A)		1,880.72		328.13

MUMBAI



B. Cash flow from investing activities			
Capital expenditure on fixed assets, including capital advance	(3,564.02)		(407.43)
Proceeds from sale of fixed assets			
Interest received			
- Others	6.65		10.49
Dividend received			
- Others	0		0.02
		(3,557.37)	(396.92)
Net income tax (paid) / refunds		(309.64)	(111.22)
Net cash flow from / (used in) investing activities (B)		(3,867.02)	(508.14)
C. Cash flow from financing activities			
Proceeds from long-term borrowings	1,661.97		90.89
Repayment of borrowings & Net increase / (decrease) in working capital borrowings	346.57		(302.09)
Proceeds from other short-term borrowings			(469.47)
Repayment of other short-term borrowings	(25.50)		(55.76)
Finance cost	(73.57)		(81.42)
		1909.476	(817.85)
Cash flow from extraordinary items			-
Net cash flow from / (used in) financing activities (C)		1,909.48	(817.85)
Net increase/(decrease) in Cash & cash equivalents (A+B+C)		(76.82)	(997.86)
Cash and cash equivalents at the beginning of the year		241.70	1,239.56
Cash and cash equivalents at the end of the year		164.88	241.70

FOR & BEHALF OF BOARD OF DIRECTORS
AURO LABORATORIES LIMITED



(SIDDHARTHA DEORAH)
WHOLE TIME DIRECTOR
DIN: 00230796



Place : Mumbai
Date : 25.05.2024



Kothari Jain & Associates

Mob. : 9637777007

Chartered Accountants

001, Shubham Heritage, Behind Gopal Building, Ambadi Road, Vasai Road (West), Palghar - 401 202.
Email : kothari_jain@hotmail.com

Date :

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF THE STANDALONE FINANCIAL RESULTS OF THE COMPANY

To the Board of Directors of Auro Laboratories Limited

We have audited the accompanying Statement of Standalone Financial Results of Auro Laboratories Limited ("the Company") for the quarter and year ended March 31, 2024, attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016.

Opinion on Annual Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

(i) is presented in accordance with requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016, and

(ii) gives a true and fair view, in conformity with aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, of the profit, total comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2024.

Basis of opinion

We conducted our audit in accordance with the Standards on Auditing issued by Institute of Chartered Accountants of India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the statement is free from material misstatement(s).



An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the statement. The procedures selected depend on auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial controls relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal financial control. An audit also includes evaluating the appropriateness of the accounting policies used and reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the statements.

We believe that the evidence obtained by us, is sufficient and appropriate to provide a basis for our audit opinion

Management's and Those Charged with Governance Responsibilities for the Statement

This Statement has been prepared on the basis of the annual financial statements. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit/loss and other comprehensive income and other financial information of the Company in accordance with the accounting principles generally accepted in India, including Ind AS prescribed under Section 133 of 'the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations including SEBI Circular. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters



related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the 'Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Statement

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under section ,143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with the Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under, Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of the management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material



uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we, conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such, disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Standalone Financial Results of the Company to express an opinion on the Standalone Financial Results.

Materiality is the magnitude of misstatements in the Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have, complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

This Statement is the responsibility of the Company's Management and is approved by the Board of Directors. The Statement as it relates to the quarter ended March 31, 2024, has been compiled from the related interim condensed standalone financial statements prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") and as it relates to the year ended March 31, 2024, had been compiled from the related annual standalone financial statements prepared under Section 133 of the Companies Act, 2013 read with rules issued thereunder and other



accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such interim condensed standalone financial statements and annual standalone financial statements.

Further, we report that the figures for the quarter ended March 31, 2024 represent the derived figures between the audited figures in respect of the financial year ended March 31, 2024 and the published year to date figures up to December 31, 2023 being the date of the end of the third quarter of the current financial year, which were subjected to a limited review as stated above as required under the Listing Regulations and circular.

The standalone annual financial results dealt with by this report have been prepared for this express purpose of filling with stock exchanges. These results are based on the audited standalone financial statement of the company for the year ended March 31, 2024 on which we issued an unmodified audit opinion vide our report dated May 25, 2024.

For Kothari Jain & Associates.

Chartered Accountants
(Firm Reg. No. 113041W)



(Sunil Kumar Kothari)
Proprietor

Membership No. 043842

UDIN: 24043842BKCOLT3151



Place: Mumbai

Date: 25/05/2024



Auro Laboratories Limited

314, T.V. Industrial Estate, S.K. Ahire Marg,
Worli, Mumbai - 400 030. India
Tel. : + 91 22 6663 5456
Fax : +91 22 6663 5460
E-mail : auro@aurolabs.com
Web : www.aurolabs.com

Reg. Off. / Mfg. Unit :
K-56, M. I. D. C. Tarapur,
Dist. Palghar, Maharashtra - 401506.
CIN No. L33125MH1989PLC051910

May 25, 2024

The Board of Directors
Auro Laboratories Limited
K 56, MIDC, Tarapur, Dist. Palghar,
Thane, Maharashtra, 401506

Dear Sir,

Sub: ***Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015***

Pursuant to the provision of Regulation 33 (3) (d) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/ CFO/CMD/56/2016 dated May 27, 2016, we hereby declared that the Statutory Auditors of the Company M/s Kothari Jain & Associates, Chartered Accountants, Mumbai (Firm Registration No. 113041W) have issued the Audit Reports with Unmodified Opinion in respect of the Audited Standalone Financial results for the quarter & year ended on March 31, 2024.

We request you to kindly take the same on record.

Thanking you,
For **Auro Laboratories Limited**

(Siddhartha Deorah)
Whole Time Director
DIN: 00230796

